3/3
10:18 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.
3/2
02:22 am
ptgx
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]
Low
Report
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]
3/1
01:42 am
ptgx
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]
Low
Report
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]
2/26
01:36 pm
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.
2/26
10:30 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.
2/26
09:55 am
ptgx
Protagonist Therapeutics (PTGX) had its price target raised by Citizens Jmp from $102.00 to $112.00. They now have a "market outperform" rating on the stock.
Low
Report
Protagonist Therapeutics (PTGX) had its price target raised by Citizens Jmp from $102.00 to $112.00. They now have a "market outperform" rating on the stock.
2/25
04:01 pm
ptgx
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit [Yahoo! Finance]
Low
Report
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit [Yahoo! Finance]
2/18
06:38 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
2/2
05:15 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
2/1
01:05 am
ptgx
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
Medium
Report
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
1/30
07:02 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/7
09:28 pm
ptgx
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
1/7
06:21 pm
ptgx
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
Medium
Report
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
1/5
09:10 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.
1/5
07:40 am
ptgx
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]
Low
Report
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]
12/25
04:12 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
12/17
07:19 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/8
07:22 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/5
04:43 pm
ptgx
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]